Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial

Drakaki A.Kirby C.J.Van Der Heijden M.S.Petrylak D.P.Powles T.Chi K.N.Fl?chon A.Necchi A.G?czi L.Lee J.-L.Gakis G.Bracarda S.Chowdhury S.CHIA-CHI LINKeizman D.Vaishampayan U.N.Zimmermann A.H.Bell-Mcguinn K.Castellano D.2022-09-152022-09-1520202352-3727https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083061281&doi=10.3233%2fBLC-190252&partnerID=40&md5=782a8cf8c84e2098fa375754c885810dhttps://scholars.lib.ntu.edu.tw/handle/123456789/620244Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trialjournal article10.3233/BLC-1902522-s2.0-85083061281